FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
The event will be attended by 35,000+ industry professionals
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
Subscribe To Our Newsletter & Stay Updated